Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II single-arm open-label study of autologous RAK cell injection in advanced renal cell carcinoma after failure of second-line treatment
CTR20252048Phase 2Active
- Sponsor
- Puhua Saier
- Start
- May 2025
- Modality
- Vaccines & Immunotherapeutics, Cell Therapies
- Countries
- 1
01
Overview
A Phase 2 trial of RAK cells in renal cell carcinoma (RCC), sponsored by Puhua Saier. Started May 2025; status: active.
02
Drugs
RAK cells
03
Conditions
renal cell carcinoma (RCC)
Beyond the preview
Go deeper on CTR20252048.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20252048.